Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.
Abnormalities in mineral metabolism are a universal complication in dialysis patients and are associated with an increased risk of cardiovascular disease and mortality. Hyperphosphatemia, increased fibroblast growth factor 23 levels and secondary hyperparathyroidism are all strongly associated with adverse outcomes in end stage renal disease (ESRD) and most treatment strategies target these parameters. Over the past few years, new therapies have emerged for the treatment of abnormalities of mineral metabolism in ESRD and many are promising. This article will review these new therapeutic options including the potential advantages and disadvantages compared to existing therapies.
Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, Colorado.|Denver Health Medical Center, Denver, Colorado.
Jessica
J
Kendrick
Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, Colorado.
Michel
M
Chonchol
D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D019468:Disease Management; D014943:Global Health; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008903:Minerals / Q000378:metabolism*; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends
D008903:Minerals